Director Of Emergent BioSolutions Makes $85K Sale

Revealing a significant insider sell on November 10, Tyagi Sujata Dayal, Director at Emergent BioSolutions (NYSE:EBS), as per the latest SEC filing.

What Happened: Dayal's recent move involves selling 8,552 shares of Emergent BioSolutions. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday. The total value is $85,520.

Tracking the Tuesday's morning session, Emergent BioSolutions shares are trading at $10.9, showing a down of 0.82%.

Get to Know Emergent BioSolutions Better

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

A Deep Dive into Emergent BioSolutions's Financials

Revenue Challenges: Emergent BioSolutions's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -21.78%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Navigating Financial Profits:

• Gross Margin: With a low gross margin of 61.31%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.

• Earnings per Share (EPS): Emergent BioSolutions's EPS reflects a decline, falling below the industry average with a current EPS of 0.96.

Debt Management: Emergent BioSolutions's debt-to-equity ratio stands notably higher than the industry average, reaching 1.14. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Navigating Market Valuation:

• Price to Earnings (P/E) Ratio: Emergent BioSolutions's current Price to Earnings (P/E) ratio of 8.33 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.

• Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.82, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio of 3.77 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Why Insider Activity Matters in Finance

Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.

Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.

However, insider sells may not always signal a bearish view and can be influenced by various factors.

Important Transaction Codes

Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Emergent BioSolutions's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.